KRAS and lung carcinoma: Compared to the 39% of patients’ samples with driver mutations and alterations who underwent sequencing of lung carcinomas at our institution, 76% of patients with CNS metastases harbored driver mutations and alterations, predominantly EGFR, KRAS, and ALK.